Abstracts tagged "renal disease and scleroderma"

Abstract Number: 2707 • 2018 ACR/ARHP Annual Meeting
Scleroderma Renal Crisis: The Association of High-Dose Steroids and Poor Outcome
Nilasha Ghosh¹, Xuan Cai² and Cybele Ghossein³, ¹Internal Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Nephrology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Scleroderma renal crisis (SRC) is the most acute and life-threatening complication of scleroderma characterized by sudden increase in blood pressure and worsening kidney function.…
Abstract Number: 835 • 2015 ACR/ARHP Annual Meeting
A Meta-Analysis to Determine If the Prevalence of Scleroderma Renal Crisis Decreasing with Time
Matthew Turk¹ and Janet E. Pope², ¹Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ²University of Western Ontario, London, ON, Canada
Background/Purpose: Systemic sclerosis (scleroderma, SSc) is an autoimmune connective tissue disease with increased mortality from various internal organ involvement. Scleroderma renal crisis (SRC) usually occurs…
Abstract Number: 837 • 2015 ACR/ARHP Annual Meeting
Exposure to ACE Inhibitors Prior to Onset of Scleroderma Renal Crisis Is Not Associated with Increased Risk of Mortality in a Large Retrospective Cohort Study
Sindhu R. Johnson¹, Mohamed Elarabi², Susanna Proudman³, Tracy M. Frech⁴, Joanne Sahhar⁵, Wendy Stevens⁶, Jane Zochling⁷, Zareen Ahmad⁸, Murray Baron⁹, Marie Hudson⁹ and Canadian Scleroderma Research Group, ¹Medicine, Toronto Scleroderma Program, Toronto Western Hospital, Toronto General Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, ²Toronto Scleroderma Program, Toronto Western Hospital, Toronto General Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, ³Rheumatology Unit, Royal Adelaide Hospital North Terrace, Adelaide, Australia, ⁴Div of Rheumatology, University of Utah, Salt Lake City, UT, ⁵Department of Rheumatology, Monash Medical Centre, Melbourne, Australia, ⁶Rheumatology, St. Vincent’s Hospital, Melbourne, Australia, ⁷Royal Hobart Hospital, Tasmania, Australia, ⁸Division of Rheumatology, Toronto Scleroderma Program, Toronto Western Hospital, Toronto General Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, ⁹Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, QC, Canada
Background/Purpose: Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis (SSc). Since the advent of angiotensin converting enzyme inhibitors (ACEI), the outcome of…
Abstract Number: 2903 • 2013 ACR/ARHP Annual Meeting
Perturbed Response To Experimental Renal Injury In a TGFβ Dependent Mouse Model Of Scleroderma
Emma Derrett-Smith¹, Mark Neal², David J. Abraham³, Alan Salama⁴, Mark A. Little² and Christopher P. Denton³, ¹Centre for Rheumatology and Connective Tissue Diseases,, UCL Medical School, London, United Kingdom, ²UCL Medical School, London, United Kingdom, ³Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ⁴Centre for Nephrology, University College London, London, United Kingdom
Background/Purpose: Scleroderma renal pathology is predominantly vascular and fibrotic without major inflammatory features. Accelerated hypertension and rapidly progressive renal dysfunction are hallmarks of scleroderma renal…
Abstract Number: 2593 • 2013 ACR/ARHP Annual Meeting
The Prognosis Of Scleroderma Renal Crisis In RNA-Polymerase III Antibody (ARA) Positive Compared To ARA Negative Patients
Bernadette Lynch¹, Henry Penn², Jennifer Harvey³, Aine Burns⁴ and Christopher P. Denton⁵, ¹Department of Rheumatology, The Royal Free Hospital, London, United Kingdom, ²Northwick Park Hospital, Harrow, United Kingdom, ³Clinical Immunology, Royal Free Hospital, London, United Kingdom, ⁴Department of Nephrology, The Royal Free Hospital, London, United Kingdom, ⁵Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom
Background/Purpose: Scleroderma renal crisis (SRC) usually presenting with accelerated hypertension and acute kidney injury (AKI) is one of the most severe complications of Systemic Sclerosis…
Abstract Number: 2591 • 2013 ACR/ARHP Annual Meeting
Scleroderma Renal Crisis and Pulmonary Arterial Hypertension Are Very Rare In The Same Patient
Bernadette Lynch¹, Vincent Sobanski^1,2, Clive Handler³, Benjamin E. Schreiber⁴, John G. Coghlan⁵, Voon H. Ong⁶, Aine Burns⁷ and Christopher P. Denton⁸, ¹Department of Rheumatology, The Royal Free Hospital, London, United Kingdom, ²Service de médecine interne, Centre National de Référence de la Sclérodermie Systémique, Hôpital Claude Huriez, CHRU Lille, Lille, France, ³Department of Pulmonary Hypertension, The Royal Free Hospital, London, United Kingdom, ⁴Royal Free Hospital NHS Foundation Trust, National Pulmonary Hypertension Service, London, United Kingdom, ⁵National Pulmonary Hypertension Service, The Royal Free Hospital NHS Foundation Trust, London, United Kingdom, ⁶Department of Rheumatology, The Royal Free and University College Medical School, London, United Kingdom, ⁷Department of Nephrology, The Royal Free Hospital, London, United Kingdom, ⁸Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus, London, United Kingdom
Background/Purpose: Systemic Sclerosis (SSc) is associated with occlusive vasculopathy resulting in digital ischaemia, telangiectasia, scleroderma renal crisis (SRC) and pulmonary arterial hypertension (PAH). SRC and…
Abstract Number: 723 • 2012 ACR/ARHP Annual Meeting
Renal Dysfunction and Disease Severity in Scleroderma-Associated Pulmonary Arterial Hypertension
Stephen C. Mathai¹, Laura K. Hummers² and Virginia D. Steen³, ¹Medicine, Johns Hopkins University, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose: Renal disease is a common complication of scleroderma (SSc). Isolated reduction in glomerular filtration rate (GFR), a marker of impaired renal function, can occur…
Abstract Number: 728 • 2012 ACR/ARHP Annual Meeting
Does the Use of Angiotensin Converting Enzyme Inhibitors Prior to Scleroderma Renal Crisis Affect Prognosis ? – Results of the International Scleroderma Renal Crisis Survey
Marie Hudson¹, Murray Baron², Solene Tatibouet¹, Daniel Furst³, Dinesh Khanna⁴ and International Scleroderma Renal Crisis Study Investigaots⁵, ¹Jewish General Hospital, McGill University, Montreal, QC, Canada, ²Pavillion A, Rm 216, Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, Canada, ³David Geffen School of Medicine, Div of Rheumatology, University of California at Los Angeles, Los Angeles, CA, ⁴Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁵Montreal
Background/Purpose: Scleroderma renal crisis (SRC) is an infrequent but life-threatening complication of systemic sclerosis (SSc). The outcome of SRC has improved considerably since the advent…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].